Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.

about

Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.

Item

http://www.wikidata.org/entity/Q38812563

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Use of prophylactic growth fac ...... view of the Medicare database.

@en

type

Item

label

Use of prophylactic growth fac ...... view of the Medicare database.

@en

prefLabel

Use of prophylactic growth fac ...... view of the Medicare database.

@en

P1476

Use of prophylactic growth fac ...... view of the Medicare database.

@en

P2093

Allan J Collins

http://www.w3.org/2001/XMLSchema#string

Jiannong Liu

http://www.w3.org/2001/XMLSchema#string

Julia T Molony

http://www.w3.org/2001/XMLSchema#string

Romina Sosa

http://www.w3.org/2001/XMLSchema#string

Scott Stryker

http://www.w3.org/2001/XMLSchema#string

Shuling Li

http://www.w3.org/2001/XMLSchema#string

P2860

A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.

Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.

Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

P2888

s00520-017-3720-x

P31

scholarly article

P356

10.1007/S00520-017-3720-X

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28456908

http://www.w3.org/2001/XMLSchema#string